Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.42 |
| ▸ | ADH1C | P00326 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.42 |
| ▸ | ADH4 | P08319 | 1/20 | 0.42 |
| ▸ | ADH7 | P40394 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28659266 | 1.00 | EPHX1 (0.48) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL28671496 | 1.00 | EPHX1 (0.48) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL28649716 | 1.00 | EPHX1 (0.48) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL28659093 | 1.00 | EPHX1 (0.48) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL28659270 | 1.00 | EPHX1 (0.48) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL28669049 | 1.00 | EPHX1 (0.48) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL28648780 | 1.00 | EPHX1 (0.48) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL21828516 | 0.89 | TSHR (0.41) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL9816794 | 0.78 | EPHX1 (0.52) | EPHX1TSHRALDH1A1ADH1BADH1C | |
| SCHEMBL234029 | 0.78 | EPHX1 (0.52) | EPHX1TSHRALDH1A1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912731-B2 | Use of silylated formiates as hydrosilane equivalents | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912731-B2 | Use of silylated formiates as hydrosilane equivalents | PFAS, EPM2A, CYP2F1 | EPHX1 839/4885TSHR 3111/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.